Lead Product(s) : P-21
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Xontogeny, LLC
Deal Size : Undisclosed
Deal Type : Financing
Details : Shifa’s lead molecule, P-21, acts as a PCSK9/LDLR-antagonist to modulate the degradation of the LDLR in the liver, thereby regulating cholesterol homeostasis.
Product Name : P-21
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 05, 2021
Lead Product(s) : P-21
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Xontogeny, LLC
Deal Size : Undisclosed
Deal Type : Financing